The Hypothesis

I suspect the transition from age-related autonomic withdrawal to pathological bladder fibrosis isn’t just a case of two things declining at once. Instead, I propose a causative feedback loop driven by the loss of neurotrophic signaling. Specifically, I hypothesize that a chronic drop in post-ganglionic cholinergic input pushes detrusor interstitial cells (DICs) from a quiescent state into an active, pathological one. Without sustained acetylcholine (ACh) signaling at muscarinic M3/M2 receptors, these cells lose their homeostatic control and transdifferentiate into α-smooth muscle actin (α-SMA) positive myofibroblasts—the main culprits behind maladaptive collagen Type I/III deposition.

Mechanistic Reasoning

In healthy tissue, acetylcholine signaling appears to keep fibrosis in check. While current data points to TGF-β1 as the primary driver of detrusor stiffening [https://pmc.ncbi.nlm.nih.gov/articles/PMC8171243/], we’ve largely overlooked how neurotransmission stabilizes the extracellular matrix. I suspect cholinergic input acts as a "brake" on the TGF-β1/Smad signaling pathway within the bladder wall. When autonomic innervation fades with age, that brake is released.

This triggers a destructive cycle:

1. Autonomic Decline: Pelvic nerve signaling drops, leading to lower cholinergic tonus.
2. Fibroblast Activation: The loss of synaptic input causes DICs to shift toward a myofibroblast phenotype, which drives ECM remodeling.
3. Tissue Stiffening: Increased collagen I/III deposition lowers wall compliance, which messes with bladder storage mechanics [https://pmc.ncbi.nlm.nih.gov/articles/PMC8171243/].
4. Afferent Hypersensitivity: The resulting fibrotic matrix physically distorts sensory afferent terminals. This leads to OAB symptoms that persist even without motor-driven contractions [https://www.ncbi.nlm.nih.gov/books/NBK482181/].

Why This Challenges Current Models

Most research views fibrosis as a reactive response to injury or inflammation. My hypothesis reframes autonomic withdrawal itself as a form of trophic injury. This explains why antimuscarinics—which block whatever receptors are left—often fail in elderly patients. They’re competing for a signal that’s already gone, and they don't fix the structural ECM damage caused by that lost neuro-protection.

Testing the Hypothesis

We can test this using a longitudinal study with transgenic mice to target cholinergic depletion:

• Experimental Group: Optogenetic silencing of pelvic nerve afferents over 6 months.
• Readout: Use qPCR and immunohistochemistry to track TGF-β1/Smad activation and α-SMA expression in the detrusor.
• Falsification: If DIC-to-myofibroblast transition happens regardless of autonomic stimulation, or if exogenous M3/M2 receptor activation fails to rescue the phenotype, the hypothesis will be rejected.

Implications

If this holds up, our therapeutic focus needs to shift from symptomatic blockade to neuro-mimetic stabilization. We should look toward regenerative strategies that use cholinergic agonists to head off the fibrotic transition before it begins. This also fits with the sex-specific surge in collagen turnover, which might be modulated by estrogen-dependent neuro-protection—potentially bridging the gap between menopause and OAB [https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0194458].